Anzeige
Mehr »
Login
Donnerstag, 22.08.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Am Anfang der Wachstumsstory: Chance auf spektakuläre Tenbagger-Gewinne
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
405 Leser
Artikel bewerten:
(2)

Sekisui Medical Co., Ltd. adopts CCH Tagetik expert solution from Wolters Kluweras budget and global management platform solution

CCH Tagetik implemented to fulfill both global common requirements and individual site requirements on a single platform

TOKYO, Jan. 21, 2022 /PRNewswire/ -- Wolters Kluwer, a global leader in professional information, software solutions and services, today announced that Sekisui Medical Co., Ltd., has adopted CCH Tagetik expert solution as a consolidated solution for both budget and global management. Sekisui Medical, a member of the Sekisui Chemical Group, offers products and services in fields such as diagnostics, pharmaceuticals and drug development. CCH Tagetik has also been adopted by the North American branches of Sekisui Medical, where it is additionally used for sales management.

Wolters_Kluwer_Logo

Prior to the introduction of CCH Tagetik, one of the main challenges of Sekisui Medical was that the status of the business represented an intensely manual activity, as it was monitored through regular data collection on Excel. In addition, the company selected CCH Tagetik with the aim of implementing a common platform for cost optimization and governance of data management rules.

As a unified platform, CCH Tagetik enables Sekisui Medical to obtain consistent and up-to-date data at any level of granularity, broken down by business segment, for example. In addition to company-wide budget and KPI management, they have achieved centralized management of data at a finely detailed level, including product-specific PL and management of fixed costs, R&D expenses and staffing. Reporting capabilities of the CCH Tagetik solution also make it easy to visualize information within the company. With the CCH Tagetik solution, it is now possible for Sekisui Medical to maintain and analyze detailed centralized data by their nearly 30,000 items, by geographic region, by commercial distribution such as B2C or B2B, and by account item such as consolidated or detailed, enabling more advanced business management. None of this was possible with their previous system.

Sekisui Medical's adoption of the CCH Tagetik expert solution targets both global common requirements and individual site requirements on a single platform. Being able to realize the consolidation of budget control and global management at the Japanese headquarters, and the required individual budget control and sales planning in North America, all on the same CCH Tagetik platform, Sekisui Medical can now benefit from a more seamless data management. Utilizing the workflow function of CCH Tagetik, it is also possible to grasp the progress of, and streamline, the collection of data.

"We are delighted that Sekisui Medical has selected CCH Tagetik. We believe that CCH Tagetik unified platform will be used to its' full potential by introducing it at each group company for companies that are active not only in Japan but also on a global level, such as Sekisui Medical," said Kumiko Minowa, General Manager, CCH Tagetik Japan. "By introducing a company-wide platform, we expect that Sekisui Medical will be able to further enhance management by making it possible to visualize comprehensive its indicators."

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the healthcare; tax and accounting; governance, risk and compliance; and legal and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.

Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

For more information about our solutions and organization, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.

Media Contacts:

Beatriz Santin
CCH Tagetik
+1 339 229 2447 office
Beatriz.santin@wolterskluwer.com

Greta Bartoli
CCH Tagetik
+39 058396811 office
greta.bartoli@wolterskluwer.com

Logo: https://mma.prnewswire.com/media/1441883/Wolters_Kluwer_Logo.jpg

© 2022 PR Newswire
Gold - Die besten Aktien für den nächsten Preisschub

Steigen Sie jetzt ein und nutzen Sie die einmalige Chance, die Ihnen der nächste Goldpreisschub bietet!

Dieser Aktienreport stellt die besten Aktien für den kommenden Goldpreisanstieg vor. Zur ausgewogenen Diversifikation eines Depots sind Engagements in Gold oder Aktien von Goldproduzenten unerlässlich. Die letzten Monate haben gezeigt, dass Goldinvestments nicht nur stabilisierend sein können, sondern auch erhebliche Gewinne ermöglichen. Nach einer Konsolidierungsphase bieten sich nun wieder spannende Einstiegsmöglichkeiten.

Nutzen Sie diese Chance!

Fordern Sie jetzt den brandneuen Spezialreport an und erfahren Sie, welche Goldaktien das größte Potenzial haben. Dieser Report ist 100 % kostenlos und hilft Ihnen, die besten Investments im Goldsektor zu identifizieren.

Sichern Sie sich jetzt Ihren kostenfreien Report.

Um Ihnen den Report zusenden zu können, geben Sie einfach Ihre E-Mail-Adresse hier ein. Sie erhalten umgehend Zugang zu Ihrem PDF-Report. Dies ist für Sie vollkommen kostenlos und unverbindlich.

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.